

1 **Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent but**
2 **clinically inapparent in cancer patients under immune checkpoint therapy**
3

4 Thomas Walle^{1,4,5,6*,#}, Sunanjay Bajaj^{1,5,6,#}, Joscha A. Kraske^{5,6}, Thomas Rösner^{5,6}, Christiane S.
5 Cussigh⁷, Katharina A. Kälber⁷, Lisa Jasmin Müller⁸, Sophia Boyoung Strobel⁷, Jana Burghaus⁷,
6 Stefan Kallenberger^{5,6}, Christoph Stein-Thöringer^{2,5,6}, Maximilian Jenzer^{5,6}, Antonia Schubert^{4,5,6,13,14},
7 Steffen Kahle^{5,6}, Anja Williams^{5,6}, Birgit Hoyler¹, Lin Zielske¹⁰, Renate Skatula¹⁰, Stefanie Sawall¹,
8 Mathias F. Leber^{1,5,6}, Russell Z. Kunes¹¹, Johannes Krisam¹², Carlo Fremd^{5,6,9}, Andreas
9 Schneeweiss⁹, Jürgen Krauss^{5,6}, Anne Katrin Berger^{5,6}, Georg M. Haag^{5,6}, Stefanie Zschäbitz^{5,6}, Niels
10 Halama^{3,5,6}, Christoph Springfeld^{5,6}, Romy Kirsten¹⁰, Jessica C. Hassel⁷, Dirk Jäger⁵, NCT
11 ANTICIPATE Investigators & Guy Ungerechts^{1,4,5,6,13}

12 NCT ANTICIPATE Investigators: Thomas Walle^{1,4,5,6*,#}, Joscha A. Kraske^{5,6}, Thomas Rösner^{5,6},
13 Christiane Cussigh⁷, Katharina Kälber⁷, Lisa Jasmin Müller⁸, Sophia Boyoung Strobel⁷, Jana
14 Burghaus⁷, Stefan Kallenberger^{5,6}, Christoph Stein-Thöringer^{2,5,6}, Maximilian Jenzer^{5,6}, Antonia
15 Schubert^{4,5,6,13,14}, Steffen Kahle^{5,6}, Anja Williams^{5,6}, Omar Abdelrahim^{5,6}, Elena Busch^{5,6}, Patrick
16 Derigs⁸, Katharina Dischinger^{5,6}, Fouad Mitri⁷, Kerstin Schmidt^{5,6}, Irfan A. Bhatti^{5,6}, Barbara Grün^{5,6},
17 Nicolas Hohmann^{5,6}, Lena Woydack^{5,6}, Xin-Wen Zhang^{5,6}, Dyke Ferber^{5,6}, Andreas Mock^{5,6}, Tillmann
18 Pompecki¹⁵, Timo Schank⁷, Carlo Fremd⁹, Andreas Schneeweiss⁹, Jürgen Krauss^{5,6}, Anne Berger^{5,6},
19 Georg M. Haag^{5,6}, Stefanie Zschäbitz^{5,6}, Niels Halama^{3,5,6}, Christoph Springfeld^{5,6}, Romy Kirsten¹⁰,
20 Jessica C. Hassel⁷, Dirk Jäger^{5,6} & Guy Ungerechts^{1,4,5,6,16}

21
22 ¹Clinical Cooperation Unit Virotherapy, German Cancer Research Center (DKFZ), Heidelberg,
23 Germany

24 ²Division Microbiome and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.

25 ³Department of Translational Immunotherapy, German Cancer Research Center (DKFZ), Heidelberg,
26 Germany.

27 ⁴German Cancer Consortium (DKTK), Heidelberg, Germany

28 ⁵Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany

29 ⁶Department of Medical Oncology, University Hospital Heidelberg, Heidelberg, Germany

30 ⁷Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg,
31 Heidelberg, Germany

32 ⁸Department of Hematology, University Hospital Heidelberg, Heidelberg, Germany

33 ⁹Department of Gynecological Oncology, National Center for Tumor Diseases (NCT), Heidelberg,
34 Germany

35 ¹⁰NCT Liquid Biobank, National Center for Tumor Diseases (NCT), Heidelberg, Germany

36 ¹¹Department of Statistics, Columbia University, New York, NY 10027, USA

37 ¹²Institute of Medical Biometry, Heidelberg University, Heidelberg, Germany

38 ¹³BioQuant & Department of Cell and Molecular Biology, Heidelberg University, Heidelberg, Germany

39 ¹⁴Division Signaling and Functional Genomics German Cancer Research Center (DKFZ), Heidelberg,
40 Germany

41 ¹⁵Department of Gastroenterology, University Hospital Heidelberg, Heidelberg, Germany

42 ¹⁶Ottawa Hospital Research Institute, Cancer Therapeutics Program, 501 Smyth Road, Ottawa,
43 Ontario, Canada

44 *Corresponding author/lead contact: T.W. t.walle@dkfz.de

45 #Equal contribution

46 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

47 **Abstract**

48 Cancer patients frequently receive immune checkpoint therapies (ICT) which may modulate
49 immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was
50 observed in a cancer patient who received the BTN162b2 vaccine under ICT. Here, we
51 analyzed adverse events (AEs) in patients of various solid tumor types undergoing (n=64) or
52 not undergoing (n=26) COVID-19 vaccination under ICT as an exploratory endpoint of a
53 prospectively planned cohort study. We did not observe clinically relevant CRS after
54 vaccination (95% CI [0,0.056]). Short term (<4 weeks) serious AEs were rare (12.5%) and
55 overall AEs under ICT were comparable to unvaccinated patients. Despite the absence of
56 CRS symptoms, we observed a pairwise-correlated set of CRS-associated cytokines
57 upregulated in 42% of patients after vaccination and ICT (>1.5fold). Hence, clinically
58 meaningful CRS appears to be rare in cancer patients under ICT and elevated serum cytokine
59 levels are common but not sufficient to establish CRS diagnosis.

60

61 **Introduction**

62 Patients with solid tumors have an increased fatality risk after infection with the SARS-CoV-2
63 coronavirus (Russell et al., 2021). Cancer patients have therefore been prioritized for
64 vaccination against SARS-CoV-2 (COVID-19 vaccination) in many countries (Ribas et al.,
65 2021; Trapani & Curigliano, 2021). Approved vaccines in Europe and the United States use
66 mRNA lipid nanoparticles or viral vectors to transiently transfect/transduce a SARS-CoV-2
67 spike mRNA/transgene which is translated in the patient's healthy cells at the site of
68 vaccination, thus strongly inducing cellular and humoral adaptive immunity (Baden et al., 2020;
69 Fendler et al., 2021; Folegatti et al., 2020; Frenck et al., 2021; Sahin et al., 2014). However,
70 cancer patients were underrepresented in clinical phase III trials leading to FDA and EMA
71 approval of these vaccines (Baden et al., 2020; Folegatti et al., 2020; Polack et al., 2020).
72 Moreover, an increasing number of cancer patients receive immunomodulatory cancer
73 therapies, mostly immune checkpoint therapies (ICT) blocking the PD-1/PD-L1 coinhibitory
74 axis for T cell activation (Haslam & Prasad, 2019). Since ICT leads to reactivation of tumor
75 antigen-reactive T cells, it is possible that ICT may also influence activation of SARS-CoV-2
76 spike protein (S1)-specific T cells. This increased T cell activation may lead to massive
77 cytokine release and subsequent clinical reactions. The body's systemic reaction to the
78 resulting release of multiple inflammatory cytokines from T and myeloid cells is called cytokine
79 release syndrome (CRS). CRS manifests itself in fever, hypotension, hypoxia and multiorgan
80 dysfunction at later stages (Lee et al., 2019). Most frequently such responses are observed
81 after adoptive T cell therapies, bispecific antibodies to the CD3 co-receptor or severe infection
82 (Fajgenbaum & June, 2020). CRS is commonly graded according to the Common Terminology
83 of Adverse Events (CTCAE) or the American Society for Transplantation and Cellular Therapy
84 (ASTCT) consensus grading (Fajgenbaum & June, 2020; Lee et al., 2019). However, fever
85 $\geq 38^{\circ}\text{C}$ alone is sufficient to establish CTCAE grade 1 CRS, which does not account for mild
86 fever as part of many appropriate immune reactions. Hence, an exhaustive differential
87 diagnosis is essential in establishing CRS (Fajgenbaum & June, 2020).

88 Au et al. recently reported a patient with CRS without evidence for infection after COVID-19
89 vaccination under ICT. This patient required hospitalization due to fever, thrombocytopenia
90 (grade 3 CTCAE 4.03, grade 1 ASTCT) as well as increased c-reactive protein levels (CRP >
91 200mg/l), prompting questions about the frequency of CRS in cancer patients under ICT.
92 However, it remains unclear how frequently CRS occurs, and whether cytokine profiles could
93 be explored to identify ICT-treated cancer patients at risk for CRS at early stages.

94 Here, we assessed adverse events, clinical laboratory data and serum cytokine responses in
95 patients undergoing combined ICT and COVID-19 vaccination as an exploratory endpoint of
96 a prospectively registered single center cohort study.

97 **Results**


98 **A pan-tumor cohort study across diverse immune combination therapies**

99 Between 2nd December 2019 and 20th July 2021, we screened 301 patients, of which 190 were
100 screened prospectively and 111 retrospectively as defined in the trial protocol (German
101 Clinical Trials Register, DRKS00022890). Of these patients, 29 patients with dermatological
102 cancers were also included in a retrospective survey study at our center (Strobel et al,
103 manuscript in revision). We recruited 220 patients with advanced solid tumors undergoing
104 immune checkpoint therapy (ICT) at our center (Figure 1A). These patients received regular
105 blood sampling before and during therapy and were monitored for adverse events. We
106 assessed the COVID-19 vaccination status of the patients within the cohort during treatment
107 follow-up and identified 64 patients who received a COVID-19 vaccine while under ICT and
108 26 patients who did not (Figure 1A, B). The remaining patients either died before the vaccine
109 was widely available (n=52), did not have their vaccination status assessed (n=52), were lost
110 to follow up (n=15), refused to disclose their vaccination status (n=5) or received COVID-19
111 vaccinations before ICT (n=6) (Figure 1A).

112 We focused further analyses on the 90 patients with known vaccination status (Table 1). 23
113 cancer types were represented within this patient group, the most frequent being skin

114 melanoma (n=21), hepatocellular carcinoma (n=11) and renal cell carcinoma (n=9) (Table 1,
 115 Figure 1C). Therapies included a variety of combinatorial immunomodulatory therapies, most
 116 frequently anti-PD-1/PD-L1 monotherapy (n=35), combined anti-PD-1 and anti-CTLA-4
 117 therapy (n=15), and a combination of anti-PD-1/PD-L1 with anti-VEGF (n=11) (Table 1, Figure
 118 1D). Despite the limited patient sizes of our cohorts, vaccinated and unvaccinated patients
 119 showed similar clinical characteristics such as sex, age, tumor type, stage, comorbidities,
 120 therapy regimen and line of therapy (Table 1) and were hence deemed suitable for further
 121 comparisons.

122



123

124 **Figure 1 - A pan-tumor cohort study across diverse immune combination therapies**
 125 (A) CONSORT flow chart indicating patient screening data and cohorts for subsequent data
 126 analysis.
 127 (B) Stacked bar-graph depicting the type of COVID-19 vaccination for vaccinated patients
 128 (n=64).
 129 (C) Stacked bar-graph indicating tumor types of vaccinated (n=64) and unvaccinated (n=26)
 130 patients.
 131 (D) Stacked bar-graph indicating immune combination therapies of vaccinated (n=64) and
 132 unvaccinated (n=26) patients.

133 **Table 1 - Characteristics of analyzed patients at baseline**
134

Characteristic	Vaccinated (n=64)	Unvaccinated (n=26)	Total (n=90)
Patient recruitment characteristics			
Vaccination period (MM/YY-MM/YY)	01/21-07/21	-	01/21-07/21
Follow-up from 1 st vaccine – days (median)	24-259 (169)	-	24-259 (169)
Start of ICT period (MM/YY-MM/YY)	03/20-05/21	07/20-07/21	03/20-07/21
Follow-up from ICT – days (median)	44-574 (254)	30-441 (203.5)	30-574 (229)
Vaccination type – n (%)			
BNT162b2	48 (75.0)	-	48 (53.3)
mRNA-1273	3 (4.7)	-	3 (3.3)
AZD1222	9 (14.1)	-	9 (10.0)
AZD1222/mRNA-1273	1 (1.6)	-	1 (1.1)
Not specified	3 (4.7)	-	3 (3.3)
Sex – n (%)			
Male	44 (68.8)	19 (73.1)	63 (70.0)
Female	20 (31.3)	7 (26.9)	27 (30.0)
Age group at treatment – n (%)			
18-60	19 (29.7)	7 (26.9)	26 (28.9)
>60	45 (70.3)	19 (73.1)	64 (71.1)
ECOG – n (%)			
0	11 (17.2)	7 (26.9)	18 (20.0)
1	46 (71.9)	13 (50.0)	59 (65.6)
2	7 (10.9)	4 (15.4)	11 (12.2)
3	0 (0.0)	2 (7.7)	2 (2.2)
4-5	0 (0.0)	0 (0.0)	0 (0.0)
Cancer type – n (%)[#]			
SKCM	15 (23.4)	6 (23.1)	21 (23.3)
LIHC	9 (14.1)	2 (7.7)	11 (12.2)
KIRC	6 (9.4)	3 (11.5)	9 (10.0)
UCA	6 (9.4)	2 (7.7)	8 (8.9)
UVM	4 (6.3)	2 (7.7)	6 (6.7)
NEC	3 (4.7)	1 (3.8)	4 (4.4)
HNSC	2 (3.1)	2 (7.7)	4 (4.4)
AEG	3 (4.7)	2 (7.7)	5 (5.6)
PAAD	2 (3.1)	-	2 (2.2)
MER	2 (3.1)	-	2 (2.2)
BRCA	2 (3.1)	1 (3.8)	3 (3.3)
Other*	10 (15.6)	5 (19.2)	15 (16.7)
UICC stage at diagnosis – n (%)			
I	8 (12.5)	4 (15.4)	12 (13.3)
II	10 (15.6)	6 (23.1)	16 (17.8)
III	11 (17.2)	8 (30.8)	19 (21.1)
IV	34 (53.1)	7 (26.9)	41 (45.6)
unknown (not IV)	1 (1.6)	1 (3.8)	2 (2.2)
Line of therapy – n (%)			
1L	38 (59.3)	15 (57.7)	53 (58.9)
2L	13 (20.3)	4 (15.4)	17 (18.9)
3-5L	10 (15.6)	6 (23.1)	16 (17.8)
≥6L	3 (4.7)	1 (3.8)	4 (4.4)
Other comorbidities – n (%)[‡]			
Arterial Hypertension	29 (45.3)	9 (34.6)	38 (42.2)
Coronary heart disease	8 (12.5)	2 (7.7)	10 (11.1)
Other Cardiomyopathy	2 (3.1)	3 (11.5)	5 (5.6)
Cerebrovascular disease/ Peripheral vascular disease	6 (9.4)	2 (7.7)	8 (8.9)
Chronic pulmonary disease	2 (3.1)	1 (3.8)	3 (3.3)
Diabetes	8 (12.5)	6 (23.1)	14 (15.6)
Other endocrine disorder	12 (18.8)	5 (19.2)	17 (18.9)
Hepatic disease	6 (9.4)	3 (11.5)	9 (10.0)
Renal disease	5 (7.8)	5 (19.2)	10 (11.1)
Rheumatic disease	2 (3.1)	3 (11.5)	5 (5.6)
No Comorbidities	4 (6.3)	0 (0)	4 (4.4)

BMI – n (%)			
<18.5	1 (1.6)	2 (7.7)	3 (3.3)
≥18.5 - <25.0	29 (45.3)	8 (30.8)	37 (41.1)
≥25.0 - <30.0	13 (20.3)	7 (26.9)	20 (22.2)
≥30.0	8 (12.5)	4 (15.4)	12 (13.3)
NA	13 (20.3)	5 (19.2)	18 (20.0)
Treatment – n (%) ^f			
PD-1/PD-L1 mono	24 (37.5)	11 (42.3)	35 (38.9)
CTLA-4 + PD-1/PD-L1	9 (14.1)	6 (23.1)	15 (16.7)
CTLA-4 mono	1 (1.6)	1 (3.8)	2 (2.2)
PD-1/PD-L1 + CTX	5 (7.8)	3 (11.5)	8 (8.9)
PD-1/PD-L1 + TKI	6 (9.4)	3 (11.5)	9 (10.0)
PD-1/PD-L1 + VEGF	9 (14.1)	2 (7.7)	11 (12.2)
PD-1/PD-L1 + RTX	2 (3.1)	-	2 (2.2)
PD-1/PD-L1 other	8 (12.5)	-	8 (8.9)
<p>* Others include Ampullary carcinoma, Adrenocortical carcinoma, Cholangiocarcinoma, Carcinoma of unknown primary, Dermal squamous cell carcinoma, Esophageal squamous cell carcinoma, Head and neck mucosal melanoma, Kidney renal papillary cell carcinoma, Lung adenocarcinoma, Neuroendocrine tumor, Oral squamous cell carcinoma and RCC – Renal cell carcinoma.</p> <p># AEG - Adenocarcinoma of the esophagogastric junction, BRCA – Breast cancer, HNSC – Head and neck squamous cell carcinoma, KIRC – Clear cell renal cell carcinoma, LIHC – Liver hepatocellular carcinoma, MER – Merkel cell carcinoma, NEC – Neuroendocrine carcinoma, PAAD – Pancreatic adenocarcinoma, SKCM – Skin cutaneous melanoma, UCA – Urothelial carcinoma, UVM – Uveal melanoma.</p> <p>* Number of patients with comorbidity listed. Patients can have multiple comorbidities.</p> <p>^f CTX – Chemotherapy, NA: not available, RTX – Radiotherapy, TKI – Tyrosine Kinase Inhibitor, VEGF – Vascular Endothelial Growth Factor Antibody. ICT – Immune Checkpoint Therapy - - Not applicable</p>			

135

136 **Cytokine release syndrome is infrequent after COVID-19 vaccination under immune**
 137 **checkpoint therapy**

138 To estimate safety of COVID-19 vaccination under ICT, we analyzed early adverse events
 139 (AE) from the first until 4 weeks after the second COVID-19 vaccination dose (Table 2, Figure
 140 2A). While fewer early local adverse events such as pain at the injection site (n=2, 3.1%) were
 141 reported in our cohort, early systemic AEs were comparable to reported AEs in cancer patients
 142 including patients under ICT (Monin et al., 2021; Waissengrin et al., 2021). The most common
 143 systemic AEs included fatigue (n=10, 15.6%), muscle weakness (n=8, 12.5%) and fever (n=4,
 144 6.3%) (Figure 2B, Table 2). Seven patients (10.9%) were hospitalized due to grade ≥3 AEs
 145 and three of these patients died (4.7%) (Figure 2B). One patient who received the BNT162b2
 146 vaccine was admitted after grade 4 anemia due to esophageal varices bleeding and recovered
 147 quickly under high-dose proton pump inhibitor therapy. A second patient experienced grade 3
 148 increase of transaminases under pembrolizumab + axitinib and the mRNA-1273 vaccine which
 149 normalized within three weeks after initial IV methylprednisolone and subsequent oral
 150 glucocorticoid tapering. Another patient already exhibited grade 2 diarrhea before BNT162b2


151 vaccination which worsened to grade 3 two weeks after vaccination. Multiplex-PCR analyses
 152 of stool showed *Clostridium difficile*, and symptoms improved after therapy with IV fluids and
 153 antibiotics. Another patient who received the AZD1222 vaccine was admitted due to grade 3
 154 diarrhea for which no infectious cause could be determined and was therefore deemed ICT-
 155 related. Symptoms resolved under IV fluids and corticosteroids with oral tapering. Two patients
 156 were admitted after CT confirmed fulminant hepatic disease progression causing cholestasis
 157 and both patients ultimately died. Finally, one patient with a history of combined severe aortic
 158 stenosis (0,8cm² aortic valve area) and aortic insufficiency died at home after cardiac
 159 decompensation with pleural effusion and lower limb edema after AZD1222 administration.

160 **Table 2 - Early adverse events after COVID-19 vaccination (<4 weeks)**



Adverse Event	Any grade	Grade ≥3
Any adverse event – n (%)	40 (62.5)	8 (12.5)
No adverse events – n (%)	24 (37.5)	62 (87.5)
Adverse event – n (%)		
Fatigue	10 (15.6)	2 (3.1)
Pain at injection site	2 (3.1)	0 (0.0)
Muscle weakness	8 (12.5)	3 (4.7)
Arthralgia	1 (1.6)	0 (0.0)
Fever	4 (6.3)	0 (0.0)
Infection	4 (6.3)	3 (4.7)
Nausea	2 (3.1)	0 (0.0)
Headache	2 (3.1)	0 (0.0)
Vomiting	1 (1.6)	0 (0.0)
Upper GI bleeding	1 (1.6)	1 (1.6)
CRS grade ≥2	0 (0.0)	0 (0.0)
Laboratory abnormalities - n (%)		
Anemia	7 (10.9)	1 (1.6)
Thrombocytopenia	8 (12.5)	1 (1.6)
Bilirubin increase	9 (14.1)	1 (1.6)
Creatinine increase	6 (9.4)	1 (1.6)
Death – n (%)	3 (4.7)	

161

A Vaccinated



Unvaccinated



162 ■ Reference range ■ BNT162b2 ■ mRNA-1273 ■ AZD1222 ■ AZD1222, mRNA ■ NA

163 **Figure 2 – Early adverse events after COVID-19 vaccination under immune checkpoint therapy**

164 (A) Schematic timeline depicting the start and duration of follow-up and vaccination timepoints of
165 vaccinated and unvaccinated patients
166 (B) Tree maps visualizing the proportion and the numbers of all and grade ≥ 3 AEs up to 4 weeks after
167 vaccination in vaccinated patients (n=64).
168 (C) Line-plots indicating platelet counts (n=61, left panel) and c-reactive protein concentrations ((CRP,
169 n=55, right panel) either after the first vaccine dose (upper panels) or second vaccine dose (lower
170 panels). Reference ranges are indicated in green shading. Lines are colored according to the
171 vaccination schema used with the color code indicated below. NA: not available.

172


173 We observed no clinically relevant CRS in our patient cohort, defined as all CRS without
174 evidence for infection identified by either the CTCAE v5.0 or ASTCT 2019 criteria (95% CI
175 [0,0.056]). We excluded patients with fever alone without constitutional symptoms, which may
176 reflect appropriate inflammatory reactions (Fajgenbaum & June, 2020). In the above-
177 mentioned case report (Au et al., 2021) CRS was associated with thrombocytopenia and c-
178 reactive protein (CRP) increase. In our cohort, only one patient experienced grade ≥ 3
179 thrombocytopenia with a platelet count of 5/nl four days after the 2nd BNT162b2 dose. This
180 patient had received gemcitabine and carboplatin three days prior to the event while still under
181 prednisolone (50mg/d) due to a grade 3 autoimmune hemolytic anemia, which started after a
182 blood transfusion two months earlier. The patient was asymptomatic, afebrile and was not
183 hospitalized. Moreover, platelet counts spontaneously normalized within 2 weeks thus making
184 CRS unlikely. We frequently observed mild ($>30\text{mg/l}$ and $>1.5\text{-fold}$) CRP increase after
185 vaccination (n= 22, 40% after 1st dose; n=17, 35% after 2nd dose) (Figure 2C). One patient
186 showed a severe CRP increase (80 to 289mg/l) peaking 7 days after the 2nd BNT162b2 dose
187 (Figure 2C). This patient was also asymptomatic including absence of fever/hypotension or
188 hypoxia, thus making CRS unlikely. Blood and urine cultures remained negative, and CRP
189 spontaneously dropped below 100mg/l within 2 weeks. Hence, we did not observe any
190 clinically apparent CRS after COVID-19 vaccination in our cohort suggesting that CRS may
191 be rare in patients under ICT and concurrent COVID-19 vaccination.

192

193 **Asymptomatic CRS-like serum response patterns after COVID-19 vaccination under ICT**

194 To evaluate cytokine responses indicative of CRS, we analyzed serum levels of CRS-
195 associated cytokines in 37 patients undergoing concurrent ICT and COVID-19 vaccination
196 with a baseline sample ≤ 6 months before vaccination and a sample ≤ 6 weeks after vaccination
197 (Figure 3A-B). We excluded one patient who had an immune related adverse event (arthritis
198 grade 3) at baseline before vaccination.

199 To analyze cytokines induced by vaccination under ICT, we performed pairwise correlation of
200 all measured cytokines, which yielded four clusters of pairwise correlated cytokine programs
201 (colored sidebars, Figure 3A). To assess the stability of this clustering we bootstrapped the
202 probability of each pair of cytokines falling into the same cluster (see Methods). Bootstrapping
203 confirmed the stability of cytokine programs 2 and 3 while the other clusters were more
204 heterogeneous (Figure 3B). Assessment of the log fold change of cytokine concentrations
205 indicated that cytokine programs 2 and 3 were upregulated after vaccination in most patients
206 although only program 2 was statistically significant when correcting for multiple comparisons
207 ($p=0.006$, $q=0.03$) (Figure 3C). Program 3 ($p=0.04$, $q=0.09$) included mediators previously
208 described in CRS after the BNT162b2 vaccine in an anti-PD-1 treated cancer patient such as
209 IL-18 and sIL-2RA (Au et al., 2021). Program 2 included hallmark CRS-cytokines and CRS-
210 mediators indicative of T cell (IL-2) and myeloid cell activation (IL-6, CXCL8 = IL-8, CCL2, sIL-
211 1R) (Figure 3D). IL-6 has been linked to CRS severity in multiple studies and surpassed
212 50pg/ml (research grade measurement) in 8 patients (22.2%), levels frequently observed in
213 patients with severe COVID-19 or CAR-T cell induced CRS (Chen et al., 2021; Galván-Román
214 et al., 2021; Hay et al., 2017) (Figure 3D). Stratification by patient characteristics revealed that
215 cytokine program 2 was predominantly upregulated after BNT162b2 vaccination although only
216 few patients received other vaccines in our study (Figure S1). Moreover, induction of cytokine
217 program 2 was more frequent in male patients across a broad array of tumor types (Figure
218 S1). Overall, our results suggest induction of CRS-related cytokines as a frequent but clinically
219 inapparent event after COVID-19 vaccination in ICT treated cancer patients.




220

221 **Figure 3 - A correlated program of CRS-related cytokines is frequently upregulated after COVID-**
 222 **19 vaccination under immune checkpoint therapy**

223 (A) Heatmap indicating spearman correlation indices of log(fold change) cytokine concentrations after
 224 COVID-19 vaccination from n=38 patients. Color bars on the sides indicate clusters obtained from
 225 hierarchical clustering.
 226 (B) Heatmap indicating probability of each pair of cytokines clustering together as calculated by
 227 bootstrapping (n=10000) from n=38 patients.
 228 (C) Heatmaps indicating $_{10}\log$ -fold change of cytokine concentrations after vaccination. Bar graph on
 229 the side indicates average $_{10}\log$ -fold change of cytokines in each row with concentrations after the first
 230 or second vaccination dose labeled according to the color code below from n=38 patients. P-values
 231 (two-tailed) were calculated using a Wilcoxon signed rank test.
 232 (D) Line-plots indicating cytokine concentrations of cytokine program 2 cytokines after vaccination
 233 from n=38 patients.

234



235

236 **Figure S1 - Cytokine program 2 upregulation stratified by patient characteristics**

237 Box-plots indicating average $_{10}\log$ (fold change) of cytokine program 2 after COVID-19 vaccination
 238 stratified according to vaccine type (left panel), sex (middle panel) or tumor type (right panel, n=38).
 239 P-value was calculated using a Mann-Whitney U-test.

240

241 **Comparable adverse events in COVID-19 vaccinated and unvaccinated patients under**

242 **ICT**

243 To assess whether vaccination increased the frequency of ICT-related adverse events at later
 244 timepoints we compared AE frequencies in vaccinated (n=64) and unvaccinated patients
 245 (n=26) over the entire course of ICT. We did not detect any significant differences in all grade
 246 or grade ≥ 3 AEs between vaccinated and unvaccinated patients under ICT (Figure 4A-B). One
 247 patient experienced CRS grade 2 before COVID-19 vaccination but no patient showed CRS
 248 after vaccination. Immune related AE were numerically more frequent in unvaccinated patients
 249 while vaccinated patients had a higher frequency of fatigue, nausea and lower grade infections
 250 although these differences were not statistically significant (Figure 4A-B, Table 3). To confirm
 251 the accuracy of this comparison, we calculated propensity scores based on age and sex and

252 matched vaccinated and unvaccinated patients according to this score (Figure S2A-B). For
253 this purpose, we assigned unvaccinated patients a "virtual" vaccination date at the same time
254 interval from the start of ICT as their vaccinated matched counterparts (Figure S2A). Again,
255 overall and grade ≥ 3 adverse events were comparable between the matched cohorts (Figure
256 S2C) suggesting that it is unlikely that COVID-19 vaccination profoundly increases the
257 incidence of severe adverse events in ICT-treated cancer patients.

258 Starting from 15th October 2020, all patients were screened for COVID-19 at every therapy
259 session generally every 1-4 weeks using a rapid antigen test fulfilling the quality criteria of the
260 German Federal Institute for Vaccines and Biomedicines. We detected two COVID-19 cases
261 in the unvaccinated cohort (7.7%, 95% CI [1.6%,22.5%]) which had to be hospitalized for
262 severe pneumonia. One patient recovered and was able to resume therapy 6 weeks later but
263 died two months after due to disease progression. The other patient died from COVID-19
264 pneumonia on the intensive care unit. We detected no COVID-19 cases in the vaccinated
265 patient cohort, despite regular screening (95% CI [0,5.6%]). Accordingly, patient serum post
266 vaccination neutralized SARS-CoV-2 S1 protein binding to recombinant human ACE2 in a
267 competitive immunoassay (Figure S3). Hence, our results corroborate the increasing evidence
268 that the here investigated COVID-19 vaccines have clinically meaningful efficacy in ICT
269 treated cancer patients (Fendler et al., 2021; Monin et al., 2021).

270 To explore whether vaccination status was associated with oncological outcomes, we
271 compared overall survival of vaccinated and unvaccinated patients (Figure 4C). Vaccinated
272 patients showed prolonged survival as compared to unvaccinated patients (HR 0.24, $p=0.002$)
273 (Figure 4C). This effect could not be explained by COVID-19 related deaths alone
274 (Supplementary Table 1) but was stable in all relevant patient subgroups (Figure S4).
275 Moreover, we confirmed this result in a Cox proportional hazards model where vaccination
276 status was the strongest predictor of prolonged overall survival (coefficient -1.54, 95% CI [-
277 2.69,-0.40], $p=0.01$) (Figure 4D). Hence, these data suggest an unexpected association of
278 COVID-19 vaccination and prolonged overall survival in our patient cohort.




Figure 4 – Comparable adverse events and prolonged overall survival in COVID-19 vaccinated immune checkpoint therapy treated cancer patients

(A-B) Grouped bar plots indicating the frequency of overall adverse event (A) or grade ≥3 adverse events (B) under immune checkpoint therapy in vaccinated (n=64) and unvaccinated (n=26) patients. (C) Kaplan-Meier curve indicating overall survival probability of vaccinated (n=64) and unvaccinated (n=26) patients under immune checkpoint therapy. P values and hazard ratios were calculated using a log-rank test.

287 (D) Forest plot indicating the results of the Cox proportional hazards model of n=90 patients with
 288 boxes indicating the \log_{10} (hazard ratio) and whiskers indicating the 95% confidence interval. P values
 289 (two-tailed) and number (no.) of events are indicated on the left.

290

291 **Table 3 – Immune related adverse events under immunotherapy in vaccinated and non-**
 292 **vaccinated patients**

293 Table indicating immune related adverse event frequencies with P values calculated using
 294 Fisher's exact test.

Characteristic – n (%)	Vaccinated (n=64)	Unvaccinated (n=26)	P value
Any AE	62 (96.9)	25 (96.2)	0.99
Grade \geq 3	31 (48.4)	18 (69.2)	0.10
AI-Pneumonitis	2 (3.1)	3 (11.5)	0.14
AI-Colitis	5 (7.8)	5 (19.2)	0.15
AI-Hepatitis	6 (9.4)	3 (11.5)	0.71
AI-Hypophysitis	3 (4.7)	1 (3.9)	0.99
AI-Pancreatitis	0 (0.0)	1 (3.9)	0.29
AI-Nephritis	2 (3.1)	1 (3.9)	0.99
AI-Thrombocytopenia	0 (0.0)	1 (3.9)	0.29
AI-Hemolytic Anemia	1 (1.6)	0 (0.0)	0.99
AI-Thyroiditis	3 (4.7)	0 (0.0)	0.55
AI-Miositis/Arthritis	3 (4.7)	1 (3.9)	0.99
AI-Radiculitis	1 (1.6)	0 (0.0)	0.99

295


296

297 **Supplementary Table 1 - Cause of death in vaccinated and non-vaccinated patients**
 298 Table indicating causes of death in vaccinated and unvaccinated patients. PD - progressive disease.

Patient vaccination status	Cause of death
Unvaccinated	COVID-19 Pneumonia
	Pulmonary metastases PD, respiratory insufficiency
	Pulmonary metastases PD, respiratory insufficiency
	Laryngeal PD, respiratory insufficiency
	Respiratory Insufficiency
	Intracerebral metastasis hemorrhage
	Liver metastases PD, liver failure
	Kidney failure
	Unknown, patient declined therapy continuation
Vaccinated	Cardiopulmonary decompensation
	Aortic stenosis, cardiopulmonary decompensation
	Hepatic metastases PD, liver failure
	Hepatic metastases PD, liver failure
	Cholangiosepsis

299

300



301

302 **Figure S2 - Comparable adverse events in sex and age matched COVID-19 vaccinated**
 303 **and unvaccinated immune checkpoint therapy treated cancer patients**

304 (A) Schema indicating the propensity score based matching procedure

305 (B) Box plots indicating the proportional difference of sex before and after propensity score


306 matching (upper panel). Xy plot indicating the empirical cumulative distribution function of

307 vaccinated and unvaccinated cohorts before and after matching.
308 (C) Bar graphs indicating frequencies of all (upper panel) or grade ≥ 3 (lower panel) adverse
309 events post (virtual) vaccination in matched vaccinated and unvaccinated patients.

310

311

312



313


314

315 **Figure S3 - S1 neutralizing antibody concentrations after COVID-19 vaccination in ICT-**
316 **treated patients**

317 Line-plot indicating neutralizing antibody concentrations of individual patients after vaccination as
318 assessed by an ACE2 S1 competitive immunoassay (research grade). Color code on the right
319 indicating vaccine used in the respective patients.

320

321



322

323 **Figure S4 – Vaccination is associated with of overall survival probability across patient**
 324 **subgroups**

325 Forest-plot indicating hazard ratios (HR, boxes) and 95% confidence intervals (CI, whiskers) of
 326 vaccinated and unvaccinated patients stratified into the subgroups indicated with the exact
 327 number (no.) of events and patients at risk for each subgroup as well as the 95% CIs indicated
 328 on the left. Hazard ratios and confidence intervals were calculated using a Log-rank test or
 329 Mantel-Hanzsel method if no events were observed in one group. Diagn.: diagnosis.

330

331 Discussion

332 In a prospectively planned cohort study, we here describe a set of CRS-related cytokines
333 commonly upregulated after COVID-19 vaccination in ICT treated cancer patients despite the
334 absence of clinical CRS phenotypes. None of our patients showed evidence for clinically
335 relevant CRS after vaccination suggesting that CRS is an infrequent event after COVID-19
336 vaccination under ICT. Moreover, comparison to unvaccinated patients suggested that
337 COVID-19 vaccination does not profoundly increase the rate of immune related or grade ≥ 3
338 adverse events but may decrease the rate of COVID-19 infection in ICT treated patients.

339 A recent case report of CRS after vaccination in a colorectal cancer patient treated with anti-
340 PD-1 ICT (Au et al., 2021) highlighted the insufficient evidence regarding vaccine-related
341 adverse events in ICT treated cancer patients. Au and colleagues presented a patient with
342 fever, thrombocytopenia, CRP increase and elevation of several cytokines including IFN- γ ,
343 sIL-2R, IL-18, IL-16, IL-10 after vaccination and ICT as compared to cytokine levels before
344 initiation of ICT and vaccination (Au et al., 2021). In our study we did not observe any CRS
345 (95%CI [0,5.6%]) after COVID-19 vaccination after both short-term (1st dose until 4 weeks
346 after 2nd dose) and long-term follow-up (med. follow-up = 24 weeks after 1st dose). Moreover,
347 AE under immunotherapy were comparable in vaccinated and unvaccinated patients. Thus,
348 CRS is likely an infrequent event under combined ICT and COVID-19 vaccination.

349 Despite the absence of clinically relevant CRS, we observed a set of CRS-related cytokines
350 coordinately and commonly induced after COVID-19 vaccination under ICT. This included the
351 CRS hallmark cytokine IL-6 and other CRS-related cytokines (CXCL8, IL-2, CCL2, sIL1-RA).
352 Induction of IL-6 has been reported after mRNA-based lipoplex tumor vaccination and
353 symptoms are generally mild and self-limiting (Sahin, Oehm, et al., 2020). Moreover, we found
354 higher IL-2 levels after vaccination, which may be explained by T cell activation and preferable
355 TH1 T cell polarization as shown in healthy adults vaccinated with BNT162b2 (Sahin, Muik, et
356 al., 2020). Our patients also showed coordinated release of CCL2 and CXCL8 levels after
357 COVID-19 vaccination which can be explained by the activation of myeloid cells by the mRNA

358 loaded lipid nanoparticles of the BNT162b2 vaccine (Liang et al., 2017). While CCL2 and IL-
359 2 were also reported to be induced in the above-mentioned case report of CRS in a mismatch
360 repair deficient colorectal cancer (CRC) patient, the CRS hallmark cytokines IL-6 and CXCL8
361 levels remained largely constant in this patient (Au et al., 2021). Our study did not include a
362 CRC or mismatch-repair deficient patient who received COVID-19 vaccination. It is possible
363 that the clinical course observed by Au et al. is a CRC or mismatch repair deficiency specific
364 effect given the distinct T cell inhibitory mechanisms in these tumors which may render T cells
365 more responsive to PD-1 disinhibition (Au et al., 2021; Pelka et al.).
366 Notably, one patient in our study experienced grade 2 CRS before any COVID-19 vaccination
367 was administered, highlighting that CRS can occur independent of vaccination under ICT and
368 may not necessarily be vaccine-related. This is particularly important in cancer patients in a
369 palliative setting with limited treatment options, as CRS treatments such as glucocorticoids
370 may impair ICT efficacy and deprive patients of an important treatment option (Iorgulescu et
371 al., 2021; Maslov et al., 2021). Our results suggest that CRS-related cytokines are commonly
372 induced after COVID-19 vaccination and not sufficient to establish the diagnosis of CRS.
373 Clinically relevant CRS should therefore be diagnosed in symptomatic patients after an
374 exhaustive differential diagnosis.

375 Two cases of severe COVID-19 (95% CI [1.6%,22.5%]) occurred in our unvaccinated cohort
376 but none in our vaccinated patients. We observed induction of neutralizing antibodies after
377 vaccination thus corroborating current evidence that COVID-19 vaccines may have
378 meaningful activity in ICT-treated cancer patients (Fendler et al., 2021) (Strobel et al,
379 manuscript in revision).

380 Vaccinated patients also showed increased overall survival (OS) in our study and vaccination
381 status was an independent predictor of OS in a Cox proportional-hazards model. This
382 observation cannot be explained by COVID-19 related mortality of unvaccinated patients
383 alone. In unvaccinated patients only one in nine deaths was caused directly by COVID-19 and
384 another one from tumor progression shortly after COVID-19 infection. Because patients

385 underwent regular rapid antigen-testing (q1w-q4w) it seems unlikely that we missed a relevant
386 number of COVID-19 cases. It is also possible that the small sample size of our heterogenous
387 cohort has skewed the survival analysis despite the similarity of vaccinated and unvaccinated
388 patients in many clinical covariates. Our results should therefore be validated in larger patient
389 cohorts. Alternatively, patients with worse disease status and symptoms may be more hesitant
390 and less likely to get vaccinated. This hypothesis is supported by the fact that unvaccinated
391 patients experienced numerically more severe adverse events even though this difference
392 was not statistically significant. This observation may also be a result of increased health
393 awareness or higher compliance regarding oncological therapy in vaccinated patients, an
394 outcome we did not assess in this study. Another possible explanation is that the cytokine
395 boost induced by vaccination may have reinforced anti-tumor immunity. Specifically, IL-2
396 induction, as observed in our vaccinated patients, can break ICT resistance in subcutaneous
397 murine models (Sun et al., 2019). Overall, the tested COVID-19 vaccines were linked to
398 favorable outcomes in our study and may have meaningful clinical activity in ICT treated
399 cancer patients.

400 Despite these important insights, our study also has several limitations which should be
401 considered in its interpretation. Adverse events under SARS-CoV-2 vaccination were not the
402 primary endpoint of this study. Therefore, sample size was not optimized for this endpoint and
403 our trial is not powered to estimate the exact frequency of rare AE under ICT and COVID-19
404 vaccination. Moreover, AE were assessed upon presentation at our day clinic every 1-6 weeks
405 and not at a standardized early timepoint as performed for randomized controlled vaccination
406 trials (Polack et al., 2020). While serious AEs were generally reported instantly, lower grade
407 AEs may be underreported due to recall bias. Finally, all serum cytokine and antibody titer
408 analyses are research grade and absolute concentrations from this study should not be used
409 to establish clinical diagnoses. Strengths of our analysis include the prospective design,
410 prospective recruitment of most patients, long-term follow-up, broad array of cancer types and
411 combination ICTs.

412 In summary, induction of CRS-related cytokines after COVID-19 vaccination is common in
413 ICT-treated cancer patients, but generally clinically inapparent and hence not sufficient to
414 define CRS. Our study supports current clinical practice of COVID-19 vaccination in cancer
415 patients under ICT.

416

417 **Methods**

418 Clinical trial

419 Patients presented in this study are part of the exploration cohort of a prospectively registered
420 cohort study (DRKS00022890). The exploration cohort consisted of 220 patients of which 166
421 were recruited prospectively and 54 retrospectively. Adult patients with advanced solid tumors
422 starting a new cancer immunotherapy either as mono- or combination therapy except adoptive
423 cell therapies were eligible for inclusion. Informed consent, hemoglobin levels $\geq 8\text{g/dl}$ when
424 additional blood samples were obtained and measurable disease according to RECIST 1.1
425 were obligatory requirements for inclusion. Patients were followed up at least every 1-6 weeks
426 depending on the treatment regimen. Adverse events (AE) were retrieved from electronic
427 patient health records and graded according to CTCAE v5.0 as per trial protocol. Other
428 metadata collected included age at time of informed consent, sex, tumor type, stage and
429 histology, mutational status, sites of metastases, history of tobacco use, pre-existing health
430 conditions, concurrent medication and survival. Pre-existing health conditions were obtained
431 from electronic patient records and defined according to the Side Effect Resource (SIDER
432 v4.1, <http://sideeffects.embl.de>). Patients also received regular (q1-q4w) clinical laboratory
433 tests including creatinine, bilirubin, CRP, hemoglobin, platelet, and leukocyte counts.
434 Additionally, patients received longitudinal blood samples for cytokine measurements before
435 the start of therapy, within 1-7 weeks after therapy initiation and every 8-12 weeks under
436 immunotherapy. COVID-19 vaccination status was assessed during regular follow-up.
437 Patients did not undergo any additional screening for determination of vaccination status.

438 The primary outcome measure of the trial was prediction of radiological response which will
439 be reported elsewhere. Secondary outcome measures included the serum proteome and
440 peripheral blood immune cell composition overall, grade 3 adverse events as well as
441 progression-free and overall survival. Patient health information is pseudonymized. The study
442 size was defined by sample size estimation based on the primary outcome parameter.

443 The trial was conducted in accordance with the declaration of Helsinki in its current edition.
444 The trial received institutional ethics review board approval at Ethics Commission I Medical
445 Faculty Heidelberg, Heidelberg University (S-373/2020, S-207/2005,) and Ethics Commission
446 II Medical Faculty Mannheim, Heidelberg University (2021-567). Trial personal was subject to
447 medical confidentiality (§ 9 Abs. 1 MBO-Ä), the general data protection regulation (DSGVO)
448 and the data protection act of the state of Baden-Württemberg (LSDG).

449 Analysis of serum cytokines and neutralizing antibodies

450 Blood was collected either peripherally or via a port catheter in coagulation matrix containing
451 serum tubes (#01.1602, Sarstedt, Germany). Samples were kept at room temperature until
452 preparation (<24h). For serum preparation, tubes were centrifuged at 2500g for 10min at room
453 temperature, and the upper phase was transferred into 500µl aliquots and stored at -80°C.
454 For both cytokine and antibody analysis we only selected patients with baseline samples not
455 older than 6 months prior to vaccination. For cytokine analysis we selected all samples
456 obtained up to 4 weeks after the 2nd vaccination dose. For antibody analysis we selected all
457 samples until the end of follow-up.

458 Serum samples were thawed and immediately analyzed in duplicates using the Legendplex
459 Cytokine Storm Panel 1 (741091, Biolegend, CA, USA), Cytokine Storm Panel 2 (741142,
460 Biolegend, CA, USA) or SARS-CoV-2 Neutralizing Antibody Assay (741127, Biolegend, CA,
461 USA) according to manufacturer's instructions and analyzed on a BD FACS Canto II flow
462 cytometer (BD, NJ, USA). Analyte concentrations were interpolated from a standard curve
463 using 5 parameter logistic regression using Legendplex Software v 2021.07.01. Cytokine

464 concentrations below the lower limit of detection were set to 0. The acquisition and processing
465 of the raw data was performed by a clinician scientist who was blinded to the patients' identity
466 and metadata and who was not involved in downstream data analysis. Notably, the patients'
467 pseudonyms contained the temporal sequence of the samples.

468 General data analysis

469 All data analysis was performed using Python 3 in a Jupyter notebook or Graph Pad Prism
470 9.2.0 (GraphPad Software Inc, CA, U.S.A.). All computer code is provided under
471 (https://github.com/wallet-maker/ANTICIPATE_COVID-19.git). Plotting was done using the
472 Matplotlib (3.4.3) and Seaborn (0.11.2) packages. Plots were arranged using Adobe Illustrator
473 2021 (25.2.2, Adobe Inc, San Jose, CA, USA).

474 Bootstrapping clustering probabilities of cytokine-cytokine pairs

475 We transformed cytokine concentrations according to the following formula $c_t = 10 \log(c+1)$ with
476 c_t as the log-1p-transformed cytokine concentration and c as the raw cytokine concentration
477 in pg/ml for all vaccinated patients. We then normalized all post vaccination log-1p transformed
478 concentrations by subtracting the respective log1p transformed cytokine concentrations of the
479 baseline sample. Based on these normalized concentrations, we then calculated a spearman
480 cytokine-cytokine correlation matrix. We calculated pairwise Euclidian distances using scipy's
481 (1.7.2) `scipy.spatial.distance.pdist` function. Using scipy's `scipy.cluster.hierarchy.linkage`
482 function with the UPGMA method, we obtained the row and column linkages from the
483 untransposed and transposed Euclidian distance matrix respectively and transformed these
484 into flat clusters by applying `scipy.cluster.hierarchy.fcluster` function using a cophenetic
485 distance of 1.6.

486 We sampled the normalized log1p transformed cytokine concentration dataframe object with
487 replacement with the same sample size as the initial dataframe and repeated the above-
488 mentioned procedure to obtain flat clusters. This sampling and clustering was repeated
489 $n=10,000$ times. For each pair of cytokines we then counted their co-occurrence in a cluster

490 and summed the values for all 10,000 separate clusterings dividing the counts for each pair of
491 cytokines by 10 000 to obtain an approximation of the probability for each pair of cytokines to
492 fall into the same cluster.

493 Survival analysis

494 Survival was analyzed by Kaplan-Meier curves and Log-rank tests (Mantel-Cox) using
495 GraphPad Prism and the lifelines package (0.26.3). We inspected the Kaplan-Meier curves
496 and did not see any obvious violation of the proportional hazards assumption. Using the
497 lifelines package, we also calculated a Cox-proportional hazards model using sex, age at trial
498 inclusion, stage, ECOG and vaccination status. We excluded BMI, tumor type and therapy
499 type. BMI was not available for several patients which would have decreased the population
500 size. When including therapy type and tumor type the Cox model did not converge, likely due
501 to the large number of categories for these variables. When no events were observed in one
502 group we reported hazard-ratios using the Mantel-Hanszel method implemented in Graph Pad
503 Prism 9.2.0. Otherwise, we used the logrank method implemented in Graph Pad Prism 9.2.0.

504 Propensity score matching

505 Propensity score matching was performed using the pymatch package (0.3.4). Propensity
506 scores were calculated for each patient based on age and sex. Based on these propensity
507 scores we assigned each unvaccinated patient a vaccinated counterpart with replacement.
508 This led to efficient matching, defined as a reduction in the age and sex imbalance of the
509 vaccinated and unvaccinated cohorts (Figure S2B). We did not include other variables into the
510 calculation of the propensity score because they led to inefficient matching with greater
511 imbalance of the cohorts after matching.

512 After matching the patients, we calculated the interval from start of immunotherapy to the first
513 COVID-19 vaccination for each vaccinated patient. By adding this interval to the start date of
514 immunotherapy of the respective matched unvaccinated patient we created a 'virtual'

515 vaccination date for each unvaccinated patient. We then compared adverse events of
516 vaccinated and unvaccinated patients after this (virtual) vaccination date.

517 Statistical analysis and estimation of CRS frequency

518 Confidence intervals for CRS frequencies were calculated as Clopper-Pearson intervals
519 based on the beta distribution using the statsmodels.stats.proportion.proportion_confint
520 function of the statsmodels package (0.10.2). P values were calculated using Wilcoxon one
521 sample tests or Wilcoxon matched-pairs signed rank tests for continuous/ordinal one sample
522 or paired two sample data respectively using scipy's scipy.stats.wilcoxon function (1.7.2). For
523 categorical data/contingency tables we used Fisher's exact test (GraphPad Prism 9.2.0). All p
524 values are two-tailed. For cytokine data analysis p values were corrected for multiple
525 comparisons with the Benjamini&Hochberg method using R 4.1.1 and the p.adjust function.
526 For clinical data analysis we did not use multiple comparisons correction to increase our power
527 to detect differences vaccine-related adverse events (which we did not find).

528 **Conflicts of interest:**

529 Thomas Walle reports previous and current stock ownership of various pharmaceutical
530 companies manufacturing SARS-CoV-2 vaccines and diagnostics including BionTech, Astra-
531 Zeneca and Roche. Thomas Walle reports research support from CanVirex, Basel,
532 Switzerland, a company developing viral vector-based immunotherapies and vaccines
533 (financial support for blood sampling materials). Guy Ungerechts is founder and current
534 CMO/CSO of CanVirex. All other authors report no conflicts of interest.

535 **Author contributions:**

536 Conceptualization: T.W.

537 Methodology: T.W. J.A.K., R.K.

538 Computer Code: T.W.

539 Investigation: T.W., S.B., J.A.K., B.H., L.Z., R.S., M.W., S.P.,

540 Patient recruitment: T.W., K.K., C.C., S.S, T.R, L.J.M., J.B., M.J., C.F., S.K., A.S., K.S., S.K.,
541 C.S-T., C.S., J.B., T.D., E.B., M.C., X.Z., A.R., M.S., F.M., M.L., A.S., D.J., J.K., G.M.H., S.Z.,
542 A.B., N.H., R.K., J.H.

543 Writing - Original Draft: T.W.,

544 Writing – Review and Editing: T.W., S.B., G.U., J.A.K., G.M.H, A.B.,C.S.

545 Visualization: T.W., S.B.

546 Funding Acquisition: T.W., G.U.

547 Supervision: G.U.

548 Statistical consultation: J.K., R.K.

549 **Funding**

550 DKFZ Clinician Scientist Program, supported by the Dieter Morszeck Foundation to T.W

551 National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany

552 German Cancer Research Center (DKFZ), Heidelberg, Germany

553 CanVirex, Basel, Switzerland to T.W./G.U.

554 **Acknowledgements**

555 We thank all participating patients and their relatives for their consent to this research. We
556 thank the NCT Day Clinic 1, Day Clinic 2 and Dermatology Outpatient Clinic nursing staff for
557 blood sampling. We thank DKFZ Flow Cytometry Core Facility for technical support and
558 infrastructure. T.W. and A.S. have been funded by a fellowship of the DKFZ Clinician
559 Scientist Program, supported by the Dieter Morszeck Foundation.

560 **Data availability statement**

561 All relevant data and code is supplied with the manuscript ([https://github.com/wallet-](https://github.com/wallet-maker/ANTICIPATE_COVID-19.git)
562 [maker/ANTICIPATE_COVID-19.git](https://github.com/wallet-maker/ANTICIPATE_COVID-19.git)). Patient material of patients who have given consent for
563 further analyses can be requested after approval of Ethics Commission I, Medical Faculty
564 Heidelberg, Heidelberg University. No custom materials have been generated during this
565 study.

566 **References**

- 567 Au, L., Fendler, A., Shepherd, S. T. C., Rzeniewicz, K., Cerrone, M., Byrne, F., Carlyle, E., Edmonds, K.,
568 Del Rosario, L., Shon, J., Haynes, W. A., Ward, B., Shum, B., Gordon, W., Gerard, C. L., Xie, W.,
569 Joharatnam-Hogan, N., Young, K., Pickering, L., Furness, A. J. S., Larkin, J., Harvey, R., Kassiotis,
570 G., Gandhi, S., Kassiotis, G., Gandhi, S., Swanton, C., Swanton, C., Fribbens, C., Wilkinson, K.
571 A., Wilkinson, R. J., Lau, D. K., Banerjee, S., Starling, N., Chau, I., Au, L., Fendler, A., Shepherd,
572 S. T. C., Byrne, F., Shum, B., Gerard, C., Young, K., Pickering, L., Furness, A. J. S., Larkin, J.,
573 Kassiotis, G., Wilkinson, K. A., Wilkinson, R. J., Banerjee, S., Starling, N., Chau, I., Turajlic, S.,
574 Turajlic, S., Crick, C.-C., & Consortium, C. (2021). Cytokine release syndrome in a patient with
575 colorectal cancer after vaccination with BNT162b2. *Nature Medicine*.
576 <https://doi.org/10.1038/s41591-021-01387-6>
- 577 Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A.,
578 Roupahel, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C.,
579 Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola,
580 J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B.,
581 Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T. (2020). Efficacy and Safety of the
582 mRNA-1273 SARS-CoV-2 Vaccine. *New England Journal of Medicine*, 384(5), 403-416.
583 <https://doi.org/10.1056/NEJMoa2035389>
- 584 Chen, L. Y. C., Hoiland, R. L., Stukas, S., Wellington, C. L., & Sekhon, M. S. (2021). Assessing the
585 importance of interleukin-6 in COVID-19. *The Lancet Respiratory Medicine*, 9(2), e13.
586 [https://doi.org/10.1016/S2213-2600\(20\)30600-7](https://doi.org/10.1016/S2213-2600(20)30600-7)
- 587 Fajgenbaum, D. C., & June, C. H. (2020). Cytokine Storm. *New England Journal of Medicine*, 383(23),
588 2255-2273. <https://doi.org/10.1056/NEJMra2026131>
- 589 Fendler, A., Shepherd, S. T. C., Au, L., Wilkinson, K. A., Wu, M., Byrne, F., Cerrone, M., Schmitt, A. M.,
590 Joharatnam-Hogan, N., Shum, B., Tippu, Z., Rzeniewicz, K., Boos, L. A., Harvey, R., Carlyle, E.,
591 Edmonds, K., Del Rosario, L., Sarker, S., Lingard, K., Mangwende, M., Holt, L., Ahmod, H.,
592 Korteweg, J., Foley, T., Bazin, J., Gordon, W., Barber, T., Emslie-Henry, A., Xie, W., Gerard, C.
593 L., Deng, D., Wall, E. C., Agua-Doce, A., Namjou, S., Caidan, S., Gavrielides, M., MacRae, J. I.,
594 Kelly, G., Peat, K., Kelly, D., Murra, A., Kelly, K., O'Flaherty, M., Dowdie, L., Ash, N., Gronthoud,
595 F., Shea, R. L., Gardner, G., Murray, D., Kinnaird, F., Cui, W., Pascual, J., Rodney, S., Mencil, J.,
596 Curtis, O., Stephenson, C., Robinson, A., Oza, B., Farag, S., Leslie, I., Rogiers, A., Iyengar, S.,
597 Ethell, M., Messiou, C., Cunningham, D., Chau, I., Starling, N., Turner, N., Welsh, L., van As, N.,
598 Jones, R. L., Droney, J., Banerjee, S., Tatham, K. C., O'Brien, M., Harrington, K., Bhide, S.,
599 Okines, A., Reid, A., Young, K., Furness, A. J. S., Pickering, L., Swanton, C., Gandhi, S., Gamblin,
600 S., Bauer, D. L. V., Kassiotis, G., Kumar, S., Yousaf, N., Jhanji, S., Nicholson, E., Howell, M.,
601 Walker, S., Wilkinson, R. J., Larkin, J., Turajlic, S., The Crick, C.-C., & The, C. C. (2021). Adaptive
602 immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following
603 vaccination in patients with cancer: the CAPTURE study. *Nature Cancer*.
604 <https://doi.org/10.1038/s43018-021-00274-w>
- 605 Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi,
606 S., Bittaye, M., Clutterbuck, E. A., Dold, C., Faust, S. N., Finn, A., Flaxman, A. L., Hallis, B., Heath,
607 P., Jenkin, D., Lazarus, R., Makinson, R., Minassian, A. M., Pollock, K. M., Ramasamy, M.,
608 Robinson, H., Snape, M., Tarrant, R., Voysey, M., Green, C., Douglas, A. D., Hill, A. V. S., Lambe,
609 T., Gilbert, S. C., Pollard, A. J., Aboagye, J., Adams, K., Ali, A., Allen, E., Allison, J. L., Anslow, R.,
610 Arbe-Barnes, E. H., Babbage, G., Baillie, K., Baker, M., Baker, N., Baker, P., Baleanu, I.,
611 Ballaminut, J., Barnes, E., Barrett, J., Bates, L., Batten, A., Beadon, K., Beckley, R., Berrie, E.,
612 Berry, L., Beveridge, A., Bewley, K. R., Bijker, E. M., Bingham, T., Blackwell, L., Blundell, C. L.,
613 Bolam, E., Boland, E., Borthwick, N., Bower, T., Boyd, A., Brenner, T., Bright, P. D., Brown-
614 O'Sullivan, C., Brunt, E., Burbage, J., Burge, S., Buttigieg, K. R., Byard, N., Cabera Puig, I.,
615 Calvert, A., Camara, S., Cao, M., Cappuccini, F., Carr, M., Carroll, M. W., Carter, V., Cathie, K.,
616 Challis, R. J., Charlton, S., Chelysheva, I., Cho, J.-S., Cicconi, P., Cifuentes, L., Clark, H., Clark, E.,
617 Cole, T., Colin-Jones, R., Conlon, C. P., Cook, A., Coombes, N. S., Cooper, R., Cosgrove, C. A.,

618 Coy, K., Crocker, W. E. M., Cunningham, C. J., Damratoski, B. E., Dando, L., Dato, M. S., Davies,
619 H., De Graaf, H., Demissie, T., Di Maso, C., Dietrich, I., Dong, T., Donnellan, F. R., Douglas, N.,
620 Downing, C., Drake, J., Drake-Brockman, R., Drury, R. E., Dunachie, S. J., Edwards, N. J.,
621 Edwards, F. D. L., Edwards, C. J., Elias, S. C., Elmore, M. J., Emary, K. R. W., English, M. R.,
622 Fagerbrink, S., Felle, S., Feng, S., Field, S., Fixmer, C., Fletcher, C., Ford, K. J., Fowler, J., Fox, P.,
623 Francis, E., Frater, J., Furze, J., Fuskova, M., Galiza, E., Gbesemete, D., Gilbride, C., Godwin, K.,
624 Gorini, G., Goulston, L., Grabau, C., Gracie, L., Gray, Z., Guthrie, L. B., Hackett, M., Halwe, S.,
625 Hamilton, E., Hamlyn, J., Hanumunthadu, B., Harding, I., Harris, S. A., Harris, A., Harrison, D.,
626 Harrison, C., Hart, T. C., Haskell, L., Hawkins, S., Head, I., Henry, J. A., Hill, J., Hodgson, S. H. C.,
627 Hou, M. M., Howe, E., Howell, N., Hutlin, C., Ikram, S., Isitt, C., Iveson, P., Jackson, S., Jackson,
628 F., James, S. W., Jenkins, M., Jones, E., Jones, K., Jones, C. E., Jones, B., Kailath, R., Karampatsas,
629 K., Keen, J., Kelly, S., Kelly, D., Kerr, D., Kerridge, S., Khan, L., Khan, U., Killen, A., Kinch, J., King,
630 T. B., King, L., King, J., Kingham-Page, L., Klenerman, P., Knapper, F., Knight, J. C., Knott, D.,
631 Koleva, S., Kupke, A., Larkworthy, C. W., Larwood, J. P. J., Laskey, A., Lawrie, A. M., Lee, A.,
632 Ngan Lee, K. Y., Lees, E. A., Legge, H., Lelliott, A., Lemm, N.-M., Lias, A. M., Linder, A., Lipworth,
633 S., Liu, X., Liu, S., Lopez Ramon, R., Lwin, M., Mabesa, F., Madhavan, M., Mallett, G., Mansatta,
634 K., Marcal, I., Marinou, S., Marlow, E., Marshall, J. L., Martin, J., McEwan, J., McInroy, L.,
635 Meddaugh, G., Mentzer, A. J., Mirtorabi, N., Moore, M., Moran, E., Morey, E., Morgan, V.,
636 Morris, S. J., Morrison, H., Morshead, G., Morter, R., Mujadidi, Y. F., Muller, J., Munera-
637 Huertas, T., Munro, C., Munro, A., Murphy, S., Munster, V. J., Mweu, P., Noé, A., Nugent, F. L.,
638 Nuthall, E., O'Brien, K., O'Connor, D., Oguti, B., Oliver, J. L., Oliveira, C., O'Reilly, P. J., Osborn,
639 M., Osborne, P., Owen, C., Owens, D., Owino, N., Pacurar, M., Parker, K., Parracho, H., Patrick-
640 Smith, M., Payne, V., Pearce, J., Peng, Y., Peralta Alvarez, M. P., Perring, J., Pfafferott, K., Pipini,
641 D., Plested, E., Pluess-Hall, H., Pollock, K., Poulton, I., Presland, L., Provstgaard-Morys, S.,
642 Pulido, D., Radia, K., Ramos Lopez, F., Rand, J., Ratcliffe, H., Rawlinson, T., Rhead, S., Riddell,
643 A., Ritchie, A. J., Roberts, H., Robson, J., Roche, S., Rohde, C., Rollier, C. S., Romani, R.,
644 Rudiansyah, I., Saich, S., Sajjad, S., Salvador, S., Sanchez Riera, L., Sanders, H., Sanders, K.,
645 Sapaun, S., Sayce, C., Schofield, E., Scream, G., Selby, B., Semple, C., Sharpe, H. R., Shaik, I.,
646 Shea, A., Shelton, H., Silk, S., Silva-Reyes, L., Skelly, D. T., Smee, H., Smith, C. C., Smith, D. J.,
647 Song, R., Spencer, A. J., Stafford, E., Steele, A., Stefanova, E., Stockdale, L., Szigeti, A., Tahiri-
648 Alaoui, A., Tait, M., Talbot, H., Tanner, R., Taylor, I. J., Taylor, V., Te Water Naude, R., Thakur,
649 N., Themistocleous, Y., Themistocleous, A., Thomas, M., Thomas, T. M., Thompson, A.,
650 Thomson-Hill, S., Tomlins, J., Tonks, S., Towner, J., Tran, N., Tree, J. A., Truby, A., Turkentine,
651 K., Turner, C., Turner, N., Turner, S., Tuthill, T., Ulaszewska, M., Varughese, R., Van Doremalen,
652 N., Veighey, K., Verheul, M. K., Vichos, I., Vitale, E., Walker, L., Watson, M. E. E., Welham, B.,
653 Wheat, J., White, C., White, R., Worth, A. T., Wright, D., Wright, S., Yao, X. L., & Yau, Y. (2020).
654 Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a
655 preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet*,
656 *396*(10249), 467-478. [https://doi.org/10.1016/S0140-6736\(20\)31604-4](https://doi.org/10.1016/S0140-6736(20)31604-4)
657 Frenck, R. W., Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B.,
658 Senders, S., Bailey, R., Swanson, K. A., Ma, H., Xu, X., Koury, K., Kalina, W. V., Cooper, D.,
659 Jennings, T., Brandon, D. M., Thomas, S. J., Türeci, Ö., Tresnan, D. B., Mather, S., Dormitzer, P.
660 R., Şahin, U., Jansen, K. U., & Gruber, W. C. (2021). Safety, Immunogenicity, and Efficacy of the
661 BNT162b2 COVID-19 Vaccine in Adolescents. *New England Journal of Medicine*.
662 <https://doi.org/10.1056/NEJMoa2107456>
663 Galván-Román, J. M., Rodríguez-García, S. C., Roy-Vallejo, E., Marcos-Jiménez, A., Sánchez-Alonso, S.,
664 Fernández-Díaz, C., Alcaraz-Serna, A., Mateu-Albero, T., Rodríguez-Cortés, P., Sánchez-
665 Cerrillo, I., Esparcia, L., Martínez-Fleta, P., López-Sanz, C., Gabriele, L., del Campo Guerola, L.,
666 Suárez-Fernández, C., Ancochea, J., Canabal, A., Albert, P., Rodríguez-Serrano, D. A., Aguilar,
667 J. M., del Arco, C., de los Santos, I., García-Fraile, L., de la Cámara, R., Serra, J. M., Ramírez, E.,
668 Alonso, T., Landete, P., Soriano, J. B., Martín-Gayo, E., Fraile Torres, A., Zurita Cruz, N. D.,

- 669 García-Vicuña, R., Cardeñoso, L., Sánchez-Madrid, F., Alfranca, A., Muñoz-Calleja, C., González-
670 Álvaro, I., Alvarado, T., Martínez, P., Javier de la Cuerda Llorente, F., Arco, C. d., Aguilar, J. M.,
671 Villalba, N., Negro, M., Contreras, E., Rey, A. d., Santiago, C., Junquera, M., Caminero, R., Val,
672 F. J., González, S., Caño, M., López, I., von Wernitz, A., Retana, B., Guerra, I., Sorando, J., Chao,
673 L., Cárdenas, M. J., Espiga, V., Chicharro, P., Rodríguez, P., Alday, I. H., Sampedro, M., Prada,
674 J., Aldama, E. R., Real, Y., Caldas, M., Casabona, S., Lanás-Gimeno, A., Camara, R. d. I., Álvarez,
675 A. F., Aguadol, B., Morell, A., Ramírez, E., Zurriaga, A. I., Abanades, M. P., García, S. R., Aranda,
676 T. G., Ruiz, M., Nieto, C. M., Serra, J. M., Sánchez-Madrid, F., Muñoz-Calleja, C., Alfranca, A.,
677 Aspa, J., Marcos-Jiménez, A., Sánchez-Alonso, S., Alcaraz-Serna, A., Mateu-Albero, T., Sánchez-
678 Cerrillo, I., Esparcia, L., Martínez-Fleta, P., López-Sanz, C., Gabriele, L., Guerola, L. d. C.,
679 Fernández, E., Calzada, M. J., Tejedor, R., Canabal, A., Albert, P., Rodríguez-Serrano, D. A.,
680 Iglesias, J., Suarez, F., Sánchez, J. A., Abad, B., Suarez, C., Santos, I. d. I., Galván-Román, J. M.,
681 Roy, E., Rodríguez-Cortés, P., García-Fraile, L., Sanz, J., Sanchez, E., Moldenhauer, F., Casado,
682 P., Curbelo, J., Gutierrez, A., Bautista, A., Giménez, N. R., Fernandez, A., Parra, P., Moyano, B.,
683 Barrios, A., Real de Asua, D., Sanchez, B., Saez, C., Ciudad, M., Navas, D., Domingo, L. C.,
684 Torresano, M. d. C. C., García, D. D., Cavero, T. A., Blanco, A. G., Ramírez, A. M., Semiglia
685 Chong, M. A., Cobos, A. G., Zurita Cruz, N. D., Fraile Torres, A. M., Sanchez-Gonzalez, C.,
686 Perpén, A. F., Pérez, C. D., Ancochea, J., Alonso, T., Landete, P., Soriano, J., Cisneros, C.,
687 Castillo, E. G., García Pérez, F. J., Girón, R. M., Marcos, C., Zamora, E., García, P. G., Castañeda,
688 S., García-Vicuña, R., González-Álvaro, I., Rodríguez-García, S., Fernández-Díaz, C., Cubas, I. L.,
689 Tomero, E. G., Castañeda, N. G., Ortiz, A. M., Valero, C., Uriarte, M., & Montes, N. (2021). IL-6
690 serum levels predict severity and response to tocilizumab in COVID-19: An observational
691 study. *Journal of Allergy and Clinical Immunology*, 147(1), 72-80.e78.
692 <https://doi.org/10.1016/j.jaci.2020.09.018>
- 693 Haslam, A., & Prasad, V. (2019). Estimation of the Percentage of US Patients With Cancer Who Are
694 Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs. *JAMA Network Open*,
695 2(5), e192535-e192535. <https://doi.org/10.1001/jamanetworkopen.2019.2535>
- 696 Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D.,
697 Harju-Baker, S., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., & Turtle, C. J. (2017).
698 Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen
699 receptor–modified T-cell therapy. *Blood*, 130(21), 2295-2306. [https://doi.org/10.1182/blood-](https://doi.org/10.1182/blood-2017-06-793141)
700 [2017-06-793141](https://doi.org/10.1182/blood-2017-06-793141)
- 701 Iorgulescu, J. B., Gokhale, P. C., Speranza, M. C., Eschle, B. K., Poitras, M. J., Wilkens, M. K., Soroko, K.
702 M., Chhoeu, C., Knott, A., Gao, Y., Lim-Fat, M. J., Baker, G. J., Bonal, D. M., Nguyen, Q.-D.,
703 Grant, G. R. L., Ligon, K. L., Sorger, P. K., Chiocca, E. A., Anderson, A. C., Kirschmeier, P. T.,
704 Sharpe, A. H., Freeman, G. J., & Reardon, D. A. (2021). Concurrent Dexamethasone Limits the
705 Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. *Clinical Cancer Research*,
706 27(1), 276-287. <https://doi.org/10.1158/1078-0432.Ccr-20-2291>
- 707 Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J.
708 H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs,
709 K., Pasquini, M., DiPersio, J. F., van den Brink, M. R. M., Komanduri, K. V., Grupp, S. A., &
710 Neelapu, S. S. (2019). ASTCT Consensus Grading for Cytokine Release Syndrome and
711 Neurologic Toxicity Associated with Immune Effector Cells. *Biology of Blood and Marrow*
712 *Transplantation*, 25(4), 625-638. <https://doi.org/10.1016/j.bbmt.2018.12.758>
- 713 Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O.,
714 Bahl, K., Brito, L. A., Salter, H., Ciaramella, G., & Loré, K. (2017). Efficient Targeting and
715 Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine
716 Administration in Rhesus Macaques. *Molecular Therapy*, 25(12), 2635-2647.
717 <https://doi.org/10.1016/j.ymthe.2017.08.006>
- 718 Maslov, D. V., Tawagi, K., KC, M., Simenson, V., Yuan, H., Parent, C., Bamnolker, A., Goel, R., Blake, Z.,
719 Matrana, M. R., & Johnson, D. H. (2021). Timing of steroid initiation and response rates to

- 720 immune checkpoint inhibitors in metastatic cancer. *Journal for ImmunoTherapy of Cancer*,
721 9(7), e002261. <https://doi.org/10.1136/jitc-2020-002261>
- 722 Monin, L., Laing, A. G., Muñoz-Ruiz, M., McKenzie, D. R., del Molino del Barrio, I., Alaguthurai, T.,
723 Domingo-Vila, C., Hayday, T. S., Graham, C., Seow, J., Abdul-Jawad, S., Kamdar, S., Harvey-
724 Jones, E., Graham, R., Cooper, J., Khan, M., Vidler, J., Kakkassery, H., Sinha, S., Davis, R.,
725 Dupont, L., Francos Quijorna, I., O'Brien-Gore, C., Lee, P. L., Eum, J., Conde Poole, M., Joseph,
726 M., Davies, D., Wu, Y., Swampillai, A., North, B. V., Montes, A., Harries, M., Rigg, A., Spicer, J.,
727 Malim, M. H., Fields, P., Patten, P., Di Rosa, F., Papa, S., Tree, T., Doores, K. J., Hayday, A. C., &
728 Irshad, S. (2021). Safety and immunogenicity of one versus two doses of the COVID-19 vaccine
729 BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *The*
730 *Lancet Oncology*, 22(6), 765-778. [https://doi.org/10.1016/S1470-2045\(21\)00213-8](https://doi.org/10.1016/S1470-2045(21)00213-8)
- 731 Pelka, K., Hofree, M., Chen, J. H., Sarkizova, S., Pirl, J. D., Jorgji, V., Bejnood, A., Dionne, D., Ge, W. H.,
732 Xu, K. H., Chao, S. X., Zollinger, D. R., Lieb, D. J., Reeves, J. W., Fuhrman, C. A., Hoang, M. L.,
733 Delorey, T., Nguyen, L. T., Waldman, J., Klapholz, M., Wakiro, I., Cohen, O., Albers, J., Smillie,
734 C. S., Cuoco, M. S., Wu, J., Su, M.-j., Yeung, J., Vijaykumar, B., Magnuson, A. M., Asinovski, N.,
735 Moll, T., Goder-Reiser, M. N., Applebaum, A. S., Brais, L. K., DelloStritto, L. K., Denning, S. L.,
736 Phillips, S. T., Hill, E. K., Meehan, J. K., Frederick, D. T., Sharova, T., Kanodia, A., Todres, E. Z.,
737 Jané-Valbuena, J., Biton, M., Izar, B., Lambden, C. D., Clancy, T. E., Bleday, R., Melnitchouk, N.,
738 Irani, J., Kunitake, H., Berger, D. L., Srivastava, A., Hornick, J. L., Ogino, S., Rotem, A., Vigneau,
739 S., Johnson, B. E., Corcoran, R. B., Sharpe, A. H., Kuchroo, V. K., Ng, K., Giannakis, M., Nieman,
740 L. T., Boland, G. M., Aguirre, A. J., Anderson, A. C., Rozenblatt-Rosen, O., Regev, A., & Hacohen,
741 N. Spatially organized multicellular immune hubs in human colorectal cancer. *Cell*.
742 <https://doi.org/10.1016/j.cell.2021.08.003>
- 743 Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc,
744 G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P.,
745 Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal,
746 S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C. (2020).
747 Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. *New England Journal of*
748 *Medicine*, 383(27), 2603-2615. <https://doi.org/10.1056/NEJMoa2034577>
- 749 Ribas, A., Sengupta, R., Locke, T., Zaidi, S. K., Campbell, K. M., Carethers, J. M., Jaffee, E. M., Wherry,
750 E. J., Soria, J.-C., & D'Souza, G. (2021). Priority COVID-19 Vaccination for Patients with Cancer
751 while Vaccine Supply Is Limited. *Cancer Discovery*, 11(2), 233-236.
752 <https://doi.org/10.1158/2159-8290.Cd-20-1817>
- 753 Russell, B., Moss, C. L., Shah, V., Ko, T. K., Palmer, K., Sylva, R., George, G., Monroy-Iglesias, M. J.,
754 Patten, P., Ceesay, M. M., Benjamin, R., Potter, V., Pagliuca, A., Papa, S., Irshad, S., Ross, P.,
755 Spicer, J., Kordasti, S., Crawley, D., Wylie, H., Cahill, F., Haire, A., Zaki, K., Sita-Lumsden, A.,
756 Josephs, D., Enting, D., Swampillai, A., Sawyer, E., D'Souza, A., Gomberg, S., Harrison, C., Fields,
757 P., Wrench, D., Rigg, A., Sullivan, R., Kulasekararaj, A., Jones, E., Seeva, P., Karampera, C., Devi,
758 A., Rahman, F., Smith, D., Owczarczyk, K., Tsotra, E., Gousis, C., Lei, M., Ghosh, S., Nintos, G.,
759 Raj, K., Gleeson, M., Bailey, K., Dillon, R., Streetly, M., Mera, A., Timbres, J., Dolly, S., Van
760 Hemelrijck, M., & Guy's Cancer Real World, E. (2021). Risk of COVID-19 death in cancer
761 patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. *British*
762 *Journal of Cancer*, 125(7), 939-947. <https://doi.org/10.1038/s41416-021-01500-z>
- 763 Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics — developing a new class of drugs.
764 *Nature Reviews Drug Discovery*, 13(10), 759-780. <https://doi.org/10.1038/nrd4278>
- 765 Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K.,
766 Quandt, J., Maurus, D., Brachtendorf, S., Lörks, V., Sikorski, J., Hilker, R., Becker, D., Eller, A.-
767 K., Grützner, J., Boesler, C., Rosenbaum, C., Kühnle, M.-C., Luxemburger, U., Kemmer-Brück,
768 A., Langer, D., Bexon, M., Bolte, S., Karikó, K., Palanche, T., Fischer, B., Schultz, A., Shi, P.-Y.,
769 Fontes-Garfias, C., Perez, J. L., Swanson, K. A., Loschko, J., Scully, I. L., Cutler, M., Kalina, W.,
770 Kyratsous, C. A., Cooper, D., Dormitzer, P. R., Jansen, K. U., & Türeci, Ö. (2020). COVID-19

- 771 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature*, 586(7830), 594-
772 599. <https://doi.org/10.1038/s41586-020-2814-7>
- 773 Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D.,
774 Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H.,
775 Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitzkreuz, A., Tolliver, C., Caspar, J., Quinkhardt,
776 J., Hebich, L., Stein, M., Hohberger, A., Vogler, I., Liebig, I., Renken, S., Sikorski, J., Leierer, M.,
777 Müller, V., Mittel-Rink, H., Miederer, M., Huber, C., Grabbe, S., Utikal, J., Pinter, A., Kaufmann,
778 R., Hassel, J. C., Loquai, C., & Türeci, Ö. (2020). An RNA vaccine drives immunity in checkpoint-
779 inhibitor-treated melanoma. *Nature*, 585(7823), 107-112. [https://doi.org/10.1038/s41586-
780 020-2537-9](https://doi.org/10.1038/s41586-020-2537-9)
- 781 Sun, Z., Ren, Z., Yang, K., Liu, Z., Cao, S., Deng, S., Xu, L., Liang, Y., Guo, J., Bian, Y., Xu, H., Shi, J., Wang,
782 F., Fu, Y.-X., & Peng, H. (2019). A next-generation tumor-targeting IL-2 preferentially promotes
783 tumor-infiltrating CD8+ T-cell response and effective tumor control. *Nature Communications*,
784 10. <https://doi.org/10.1038/s41467-019-11782-w>
- 785 Trapani, D., & Curigliano, G. (2021). COVID-19 vaccines in patients with cancer. *The Lancet Oncology*,
786 22(6), 738-739. [https://doi.org/10.1016/S1470-2045\(21\)00250-3](https://doi.org/10.1016/S1470-2045(21)00250-3)
- 787 Waissengrin, B., Agbarya, A., Safadi, E., Padova, H., & Wolf, I. (2021). Short-term safety of the
788 BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint
789 inhibitors. *The Lancet Oncology*, 22(5), 581-583. [https://doi.org/10.1016/S1470-
790 2045\(21\)00155-8](https://doi.org/10.1016/S1470-2045(21)00155-8)
- 791